All News

RheumNow Podcast square

Weak Data (1.24.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com, and features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025, and why she is an inspiration.

Read Article
heart.EKG_.CVD_.jpg

Cardiovascular Risk in Cutaneous Lupus Erythematosus

Jack Cush, MD

A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.

Read Article
Lung,AI,Pleura

Lung Involvement in Still's Disease

Jack Cush, MD

A multicentre registry observational study assessed lung involvement in a cohort of Still’s disease patients, affirming pleuritis as most common and that parenchymal lung inflammatory disease is very uncommon in both children and adults.

Read Article
RheumNow Podcast square

Fallen Angels (1.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.

Read Article
Covid lung pneumonia corona (keep)

Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C)

Jack Cush, MD

A nationwide cohort study of patients with multisystem inflammatory syndrome in children (MIS-C), a life-threatening complication of COVID-19 infection, showed that many had severe disease during the acute phase, but most recovered quickly and had a reassuring midterm prognosis.

Read Article
RheumNow Podcast square

Alive in 2025 (1.10.2025)

Jack Cush, MD

Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com

Read Article
pill,ASA,colchcine,small

Does Colchicine Lower Gout Mortality Risk?

Jack Cush, MD

Data from a large UK database finds that gout patients starting urate-lowering therapy (ULT) will benefit from added colchicine prophylaxis by having fewer cardiovascular events.

Read Article
CV,risk,MI,heart,cardiac

A Modifiable Vascular Risk in SLE

MedPage Today

Atherosclerosis progression was more than twice as common in younger people with SLE than in healthy controls in a prospective study from Greece, but the rate difference narrowed substantially with sustained SLE remission and conventional cardiovascular risk factor management.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus

Jack Cush, MD

Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).

Read Article
Cardiovascular Risk in Cutaneous Lupus Erythematosus A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients. https://t.co/3gEkFBK8wc https://t.co/kagpp7w7nE

Links:

Dr. John Cush RheumNow ( View Tweet)
Lung Involvement in Still's Disease A multicentre registry observational study assessed lung involvement in a cohort of Still’s disease patients, affirming pleuritis as most common and that parenchymal lung inflammatory disease is very uncommon in both children and adults.… https://t.co/bUvg4xQrsr https://t.co/fz7wiNU0Xx
Dr. John Cush RheumNow ( View Tweet)
A Modifiable Vascular Risk in SLE Atherosclerosis progression was more than 2x as common in younger people with SLE than in healthy controls in a prospective study from Greece. https://t.co/zGTGin664D https://t.co/ZO9UlIPNIi

Links:

Dr. John Cush RheumNow ( View Tweet)
In #RA, Higher levels of ESR and CRP, but not DAS28, joint counts or global assessments, were significantly associated with the risk of incident ILD in RA. German biologics (RABBIT) registry study compared 139 RA-ILD vs vs 686 controls. https://t.co/IB7aS6IKgT https://t.co/0zN5N7w65l

Links:

Dr. John Cush RheumNow ( View Tweet)
Does Colchicine Lower Gout Mortality Risk? Data from a large UK database finds that gout patients starting urate-lowering therapy (ULT) will benefit from added colchicine prophylaxis by having fewer cardiovascular events. https://t.co/89BXT5OnVS https://t.co/N4IQzRpcPk

Links:

Dr. John Cush RheumNow ( View Tweet)
Data from Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative & Stockholm Psoriasis Cohort (n=769 Pso Pts) finds that PsO severity (PASI) PASI assoc w/ GlycA levels (syst inflammation) & GlycA levels assoc w/ CVD risk (OR=1.23) https://t.co/IwUHILMpnI https://t.co/DnEF3yuTvg

Links:

Dr. John Cush RheumNow ( View Tweet)
A Modifiable Vascular Risk in SLE Atherosclerosis progression was more than 2x as common in younger people with SLE than in healthy controls in a prospective study from Greece. https://t.co/IibXiitVY8 https://t.co/XHBQcdcMAE

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read JAMA ILD Review article. ILD= 33% idiopathic (IPF) + 15% hypersensitivity pneumonitis + 25% from CTD. 30% of ILD has cough Chest CT 91% sensitive, 71% specific 5% decr in FVC/12 mos assoc w/ 2-fold incr in mortality Rx options nintedanib or pirfenidone, TCZ, MMF, RTX… https://t.co/s5v3XD8QmC https://t.co/iP5yFWkQwb
Dr. John Cush RheumNow ( View Tweet)
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w5G1dEF7Vm https://t.co/cyiQqGBf01 https://t.co/r909qqIh4V

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read JAMA ILD Review article. ILD= 33% idiopathic (IPF) + 15% hypersensitivity pneumonitis + 25% from CTD. 30% of ILD has cough Chest CT 91% sensitive, 71% specific 5% decr in FVC/12 mos assoc w/ 2-fold incr in mortality Rx options nintedanib or pirfenidone, TCZ, MMF, RTX… https://t.co/FKZyNU1s06 https://t.co/w5q0hOesEH
Dr. John Cush RheumNow ( View Tweet)
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/w76dY29bwe https://t.co/1LBevDunjH https://t.co/Ix3UxeGUe2

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×